Table 1.
Characteristics of MG patients.
| Total | Low | Moderate | High | p-value | |
|---|---|---|---|---|---|
| Self-reported MG severity, n (%) n = 1329 | 1399 | 469 (35.3) | 690 (51.9) | 170 (12.8) | |
| Age, median (IQR). n = 1329 | 67 (54–76) | 66 (54–75) | 66 (54–76) | 68 (55–77) | 0.376a |
| Age at onset of myasthenic symptoms, median (IQR). n = 1257 | |||||
| Male | 62 (51–70) | 61 (51–69) | 63 (52–70) | 60,5 (49–70) | 0.498 a |
| Female | 39 (24–57) | 37 (24–55) | 41 (25–58) | 34 (20–56) | 0.148 a |
| Gender n = 1327 | |||||
| Male | 605 (45.6) | 248 (53.1) | 280 (40.6) | 77 (45.3) | < 0.001b |
| Female | 722 (54.4) | 219 (46.9) | 410 (59.4) | 93 (54.7) | |
| Education degree n = 1245 | |||||
| Basic | 62 (5.0) | 19 (4.3) | 33 (5.2) | 10 (6.2) | 0.014a |
| Secondary | 778 (62.5) | 260 (58.4) | 422 (66.1) | 96 (59.3) | |
| Higher | 405 (32.5) | 166 (37.3) | 183 (28.7) | 56 (34.6) | |
| Marital status n = 1325 | |||||
| Married/partnership | 986 (74.4) | 358 (76.3) | 497 (72.3) | 131(77.5) | 0.225a |
| Single | 106 (8.0) | 38 (8.1) | 61 (8.9) | 7 (4.1) | |
| Divorced/widowed | 233 (17.6) | 73 (15.6) | 129 (18.8) | 31 (18.3) | |
| Duration of MG disease in years, median (IQR). n = 1329 | 9 (4–18) | 10 (4–18) | 9 (4–18) | 11 (5–22) | 0.041a |
| Latency of diagnosis in years, median (IQR). n = 1250 | 0 (0–1) | 0 (0–1) | 0 (0–2) | 0 (0–2) | < 0.001a |
| Myasthenic crisis. n = 1384 | 240 (17.2) | 44 (9.4) | 116 (16.8) | 67 (39.4) | < 0.001b |
| Myasthenic exacerbation. n = 1384 | 319 (22.8) | 79 (16.8) | 194 (28.1) | 46 (27.1) | < 0.001b |
|
Other autoimmune diseases n = 1280 |
264 (18.9) | 81 (17.3) | 155 (22.5) | 28 (16.5) | 0.047b |
| Cardiovascular diseases. n = 1289 | 253 (18.1) | 72 (15.4) | 139 (20.1) | 42 (24.7) | 0.010b |
| Thymectomy. n = 1302 | 600 (42.9) | 212 (45.2) | 303 (44.0) | 85 (50.0) | 0.295b |
| Pyridostigmine. n = 1328 | 888 (63.5) | 253 (54.0) | 505 (73.2) | 130 (76.5) | < 0.001b |
| Delayed-release Pyridostigmine retard. n = 1329 | 545 (39.0) | 125 (26.7) | 341 (49.4) | 79 (46.5) | < 0.001b |
| Azathioprine. n = 1329 | 613 (43.8) | 194 (41.4) | 360 (52.2) | 59 (34.7) | < 0.001b |
| Steroids. n = 1251 | 328 (23.4) | 71 (15.2) | 193 (28.0) | 64 (37.6) | < 0.001b |
| Mycophenolate Mofetil. n = 1329 | 126 (9.0) | 27 (5.8) | 68 (9.9) | 31 (18.2) | < 0.001b |
| Methotrexate. n = 1329 | 53 (3.8) | 21 (4.5) | 20 (2.9) | 12 (7.1) | 0.037b |
| Ciclosporine A. n = 1329 | 15 (1.1) | 0 (0.0) | 12 (1.7) | 3 (1.8) | 0.016b |
| Rituximab. n = 1329 | 47 (3.4) | 5 (1.1) | 21 (3.0) | 21 (12.4) | < 0.001b |
| Intravenous immunoglobulin. n = 1329 | 115 (8.2) | 11 (2.3) | 57 (8.3) | 47 (27.6) | < 0.001b |
| MGQOL15 score, median (IQR). n = 1037 | 12 (4–26) | 4 (1–10) | 18 (9–29) | 25 (9–385) | < 0.001a |
| Sleep difficulties. n = 1183 | 881 (63.0) | 247 (52.7) | 512 (75.2) | 122 (71.8) | < 0.001b |
| Sexual dysfunction. n = 1209 | 755 (54.0) | 201 (42.9) | 442 (64.1) | 112 (65.9) | < 0.001b |
| BSFC score, median (IQR). n = 977 | 3 (0–10) | 1 (0–4) | 4 (0–12) | 9 (2–15) | < 0.001a |
N = 1399.
ICU Intensive care unit
P-values refer to overall group comparisons of patients with low, moderate and high MG severity. P-values < 0.05 are marked in bold numbers.
aKruskal-Wallis-Test, bChi-square test.